| Trial ID: | L6656 |
| Source ID: | NCT04304261
|
| Associated Drug: |
Canagliflozin
|
| Title: |
Effects of SGLT2i on the Cognitive Function in T2DM Patient (ESCDP)
|
| Acronym: |
ESCDP
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 2|Cognitive Functions Confusion
|
| Interventions: |
DRUG: Canagliflozin|DRUG: Sitagliptin
|
| Outcome Measures: |
Primary: Changes of cognitive function assessed by cognitive function scale, cognitive function scale, 12 weeks | Secondary: Changes of standardized uptake values of brain and splanchnic organs assessed by 18F-PET-CT, 18F-PET-CT, 1 week|Changes of brain function assessed by near infrared brain functional imaging, near infrared brain functional imaging, 4 week|Changes of urinary sodium and glucose excretion (mmol/24h), urinary sodium and glucose excretion, 1 week
|
| Sponsor/Collaborators: |
Sponsor: Third Military Medical University
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE3
|
| Enrollment: |
100
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2021-07-01
|
| Completion Date: |
2024-04-30
|
| Results First Posted: |
|
| Last Update Posted: |
2024-05-30
|
| Locations: |
Zhiming Zhu, Chongqing, Chongqing, 400042, China
|
| URL: |
https://clinicaltrials.gov/show/NCT04304261
|
